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A liquid chromatography method was developed and validated for the determination of gemifloxacin 
in human plasma using chloramphenicol as internal standard to achieve lower quantification limit. 
Acetonitrile was used to precipitated and extracted analyte and internal standard from plasma by Protein 
Precipitation. Analysis was performed isocratically on C18 column using 25% acetonitrile and 75% 0.02 
M phosphate buffer as mobile phase. The method was demonstrated to be linear from 0.003 µg/mL to 
5 µg/mL with the lower limit of quantitation of 0.003 µg/mL. The method was successfully applied 
for the bioequivalence study of gemifloxacin after a single oral administration of 320 mg gemifloxacin 
mesylate tablets to 12 healthy volunteers.
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INTRODUCTION
Gemifloxacin mesylate is a synthetic broad-
spectrum antibacterial agent for oral administration. 
Gemifloxacin, a compound related to the fluoroquinolone 
class of antibiotics, is available as the mesylate salt in 
the sesqui hydrate form. Chemically, gemifloxacin is 
(R,S)-7[(4Z)-3-(aminomethyl)-4-(methoxyimino)-1-
pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-
oxo1,8-naphthyridine-3-carboxylic acid (Figure 1). It 
is used in the treatment of acute bacterial exacerbation 
of chronic bronchitis and mild-to-moderate pneumonia. 
Gemifloxacin has been shown to be active against most 
strains of microorganisms. It is particularly active against 
Gram-positive organisms including penicillin, macrolide, 
and quinolone resistant Streptococcus pneumoniae (Calvo, 
Gimenez, 2002; Oh et al., 1996; Johnson et al., 1999; 
Berry et al., 2000; Hardy et al., 1999). Gemifloxacin acts 
by inhibiting DNA synthesis through the inhibition of both 
deoxyribonucleic acid (DNA) gyrase and topoisomerase 
IV (TOPO IV), which are essential for bacterial growth.
Literature survey revealed that analytical methods 
have been reported for the estimation of gemifloxacin, 
they include high performance liquid chromatography 
tandem mass spectrometry (Doyle et al., 2000; Ramji et 
al., 2001), microchip electrophoresis (Seung et al., 2004), 
chiral high performance liquid chromatography (Hee et 
al., 2009) and chiral countercurrent chromatography (Eun, 
Yoo-Mo, Doo, 2004; Myung et al., 2002). Simple and 
sensitive ion pairing spectrophotometric methods have 
been described for the assay of gemifloxacin mesylate by 
Marothu and Dannana (2008). Barbosa and co-workers 
(Barbosa et al., 1997) studied dissociation constants of 
series of compounds including diuretics and quinolones 
in several acetonitrile: water mixtures, high performance 
liquid chromatography by UV detector (Sultana et al., 
2011), with fluorescence detection (Allen et al., 2000b; 
Al-Hadiya et al., 2010), high performance thin-layer 
FIGURE 1 - Chemical structure of gemifloxacin and 
chloramphenicol.
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chromatography (HPTLC) with fluorescence detection 
(El-Koussi et al., 2014). The aim of the present study was 
to establish an efficient, reliable, accurate, sensitive and 
reproducible method for the application in bioequivalence 
study of gemifloxacin tablets 320 mg.
MATERIAL AND METHODS
Subjects
Twelve healthy male and female volunteers with 
mean weight of 65.6±11 kg, mean height of 164.6±7.8 
cm and mean age of 32.2±8.4 years were enrolled into the 
study. All volunteers had normal paraclinical parameters.
Exclusion criteria were as follows: Consumption 
of tobacco in any form in study day, Addiction to alcohol 
or history of any drug abuse, History of kidney or liver 
dysfunction, History of jaundice in the past 6 months, 
History of drug allergy to the test drug or any chemically 
similar to the drug under investigation, Administration / 
intake of any prescription or OTC medication for 2 weeks 
before the study, Patient suffering from any chronic illness 
such as arthritis and asthma, Subject suffering from any 
psychiatric (acute or chronic) illness, Participation in any 
bioavailability / bioequivalence study in the past 12 weeks, 
Intake of barbiturates or any enzyme – inducing drug in 
the past 3 months and HIV positive volunteers.
Study design and blood samples
This  was a  laboratory-bl ind,  s ingle-dose, 
randomized, 2-way cross-over study with a wash-out 
period of 7 days between the clinic (blood sampling) days 
to compare the pharmacokinetics of gemifloxacin (test 
product) and Factive® (reference product).
Body temperature, heart rate and blood pressure 
were recorded before drug administration on clinic days. 
Heart rate and blood pressure recordings were repeated 
at approximately 4 and 6 hours after drug administration. 
After insertion of an indwelling venous cannula, pre-dose 
blood samples had been drawn. Six Subjects received 
Gemifloxacin Tablets (test product, 320 mg) and the other 
six subjects received reference Factive® Tablets (320 mg) 
with 240 mL drinking water. The only food allowed was 
standardized meals served 6 hours and a standardized 
breakfast 3 hours after drug administration. No restrictions 
on the intake of food and fluid applied after the subjects 
had been discharged from the clinic. Gemifloxacin was 
assayed in plasma samples collected from 12 subjects, 
and data from 12 subjects were evaluated. Venous blood 
samples will be collected into heparinized, glass tubes, 
labeled as per-treatment phase, according to the following 
time schedule: before drug administration and at 0.33, 
0.67, 1, 1.33, 1.67, 2, 2.33, 2.67, 3, 3.5, 4, 6, 8, 10, 12 and 
24 hours after drug administration (18 samples per subject 
per profile period).
Bioanalytical methods
A liquid chromatography method was developed 
and validated for the determination of gemifloxacin in 
human plasma as per FDA and ICH guidelines. Extraction 
procedure as described below. 
100 µL chloramphenicol 30 mg/L is added to 1500 
µL of plasma as an internal standard and mix. 1500 µL 
acetonitrile is added to plasma and is vortexed for 10 
second then 100 µL sulfuric acid 2M is added. After 
mixing, sodium chloride is added and centrifuge at 4000 
rpm for 10 minutes. The organic phase is dried and then 
reconstitute with 100 µL of mobile phase. 50 µL of this 
sample was injected into the HPLC. 
Chromatographic conditions
The Knuer EA4300 HPLC pump and Knuer E4310 
detector were used for bioanalytical assay of standards 
and human samples. Mobile phase consisted of phosphate 
buffer (0.02 M) and acetonitrile (75:25) and the pH of 
mixture adjust to 3.0 with phosphoric acid and pumped at 
the flow rate of 1 mL/min through the 250 mm C18 column. 
The wavelength of detector for monitoring of peaks was 
275 nm. Representative chromatograms of blank plasma, 
plasma of one volunteer and standard chromatogram are 
shown in Figure 2. 
Calibration curve
Standard samples were prepared as mentioned before 
(Bioanalytical Methods). The method has good linearity 
(r>0.999) over the concentration rang 0.003 – 5.000 µg/
mL. The equation of line was y=0.53199x+0.02165 and 
the limit of quantification was 0.003 µg/mL. Inter-day 
and intra-day precision and accuracy and stability of 
this method shows that this is the validated method for 
determination of gemifloxacin in human plasma.
Precision and accuracy 
Accuracy is measured as % bias and precision is 
measured as coefficient of variation (%CV). 
For the assignment of a valid calibration range bias 
is taken as measure of accuracy and coefficient of variation 
(%CV) is taken as measure of precision. Intra-day 
accuracy and precision for a valid range must be within 
15% but within 20% at the lower limit of quantification.
Summarize inter-day and intra-day accuracy and 
precision during assay validation are in Table I to II.
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Stability
The stability of gemifloxacin in plasma was 
investigated in samples obtained from a spiked plasma at 
two concentrations. Three plasma samples were analysed 
three months after storage at −20 °C.
Analysis of long-term storage stability, three cycle 
freeze-thaw stability, bench top stability, stock solution 
stability shows gemifloxacin was stable in plasma for at 
least three months when stored at −20 °C (Table III).
FIGURE 2 - Representative chromatograms of a) blank plasma b) standard chromatogram (0.7 µg mL-1) and c) plasma of one 
volunteer (3 hours).
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TABLE I - Inter-day precision
0.0030 µg/mL 1.0 µg/mL 5.0 µg/mL
1 0.0025 1.1 5.0
2 0.0032 1.1 5.0
3 0.0028 1.1 5.1
4 0.0034 0.9 5.1
5 0.0036 1.1 5.1
Average 0.0031 1.06 5.06
RSD 14.4 8.4 1.1
TABLE II - Intra-day precision and accuracy
0.0030 µg/mL 1.0 µg/mL 5.0 µg/mL
1 0.0029 1.1 5.0
2 0.0034 1.1 5.1
3 0.0025 0.9 5.0
4 0.0024 1.0 4.9
5 0.0032 1.1 5.1
Average 0.0029 1.04 5.02
RSD 15.0 8.6 1.7
Accuracy 96.7 104 100.4
TABLE III – Gemifloxacin stability
long-term storage stability 
(three months)
freeze-thaw stability 
(three cycle) bench top stability stock solution stability
Spiked 
concentration 
(µg/mL)
0.0030 5.0 0.0030 5.0 0.0030 5.0 0.0030 5.0 
Average 0.0027 4.9 0.0028 5.0 0.0031 5.0 0.0030 4.9
Accuracy 90.0 98 93.3 100 103.3 100 100.0 98
%CV 0.00152 0.05773 0.00115 0.11547 0.00058 0.05773 0.00058 0.05774
mean ratio of the pharmacokinetic variables Cmax, 
Tmax, AUC0-10, AUC0-Inf, fall within the conventional 
bioequivalence range of 80% to 125%. 
The results of this study indicate that the test product 
with assay of 105.8% for test product of Gemifloxacin 
is bioequivalent to the reference product (Factive®) 
with respect to both the rate and extent of absorption of 
Gemifloxacin.
Under Medication Guide of Factive® tablets 
which has been approved by the U.S. Food and Drug 
Administration it was reported that following repeat 
oral doses of 320 mg of Factive® tablets to healthy 
subjects (FACTIVE® Tablets-FDA), and in another 
study “The effect of food on the bioavailability of oral 
gemifloxacin in healthy volunteers” (Allen et al., 2000a, 
the pharmacokinetics parameters were compare with this 
study in Table V. Comparison of this results with our study 
shows its similar to other studies.
CONCLUSION
It is thus concluded that the proposed method 
is simple, cost effective, accurate, safe and precise. 
A specific LC method, with a single step Protein 
Precipitation procedure, has been developed and 
validated (as per FDA and ICH forguidelines) for 
FIGURE 3 - Mean plasma volunteers curve.
RESULTS
Plasma sample from twelve healthy volunteers at 
0, 0.33, 0.67, 1, 1.33, 1.67, 2, 2.33, 2.67, 3, 3.5, 4, 6, 8, 
10, 12 and 24 hours were collected and were analyzed as 
mentioned before in section “Bioanalytical Methods”. 
The mean pharmacokinetic parameters such as maximum 
concentration (Cmax), time to reach Cmax (Tmax), area under 
curve from time zero to 24 hours (AUC0-24) and area under 
curve from time zero to infinite (AUC0-∞) are presented in 
the Table IV. The mean plasma volunteers curve is shown 
in Figure 3. 
The 90% confidence intervals for the “test/reference” 
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the determination of gemifloxacin in human plasma 
supporting a pharmacokinetic and bioequivalence study 
comparison of other study (FACTIVE® Tablets-FDA). 
The statistical analysis demonstrated that none of the 
parameters accepted for drug bioavailability (AUC0-t 
and Cmax) were not significantly different between the 
treatments for the single dose data. Moreover, it indicated 
that the two pharmaceutical products showed similar 
bioavailability profiles and therefore are considered 
bioequivalent with regard to the extent and rate of 
absorption and, interchangeable as well, for clinical and 
therapeutic purposes. 
The proposed method to analyze gemifloxacin in 
plasma by HPLC with UV detection happens to be first 
of its kind described so far in the literature. This new 
method with low LOQ (0.003 µg/mL) will be helps for 
carrying out pharmacokinetic study of gemifloxacin in 
laboratories that lack sophisticated analytical instrument 
of LC-MS/MS.
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